Dr. Gopakumar Vasydeva Iyer, MD

Dr. Iyer practices at Memorial Sloan Kettering Cancer Center in New York, New York, part of Memorial Sloan Kettering Cancer Center.

Dr. Iyer's NPI, 1689792756, was assigned on March 27, 2007. Dr. Iyer graduated from Vanderbilt University School Of Medicine in 2003. Dr. Iyer holds New York license 247043.

Dr. Iyer's primary practice is Memorial Sloan Kettering Cancer Center, at 1275 York Avenue, New York, NY 10065.

Dr. Iyer's primary practice is Memorial Sloan Kettering Cancer Center in New York, New York, part of Memorial Sloan Kettering Cancer Center. The medical group on file is Memorial Sloan Kettering Cancer Center. Dmand AI also links Dr. Iyer to 1 more medical group, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Iyer practices. Vendor and product names are available with a free account.

Internal medicine is Dr. Iyer's primary specialty in the NPI Registry, under taxonomy code 207R00000X. Dr. Iyer is board certified in medical oncology by the American Board of Internal Medicine. Dmand AI has Dr. Iyer's licenses on file in 4 states: New York, Florida, New Jersey and Michigan.

Dmand AI lists fluid and electrolyte imbalances and prostate cancer among the conditions Dr. Iyer treats.

CMS data shows 694 Medicare services from Dr. Iyer across 3 procedure codes in 2024, all of them office visits, for 160 Medicare patients. Medicare paid $62,677 for them. Every service was in an office.

CMS counts 160 Medicare patients who saw Dr. Iyer in 2024. The largest group is 75 to 84, with 80 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 11% are also on Medicaid. Their average risk score is 2.74, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Iyer's median patient age at 76, with 31% women.

In 2024, Dr. Iyer wrote 418 Medicare Part D claims for 99 patients. 91% of them were for generic drugs. CMS names the drug for 214 of them, across 10 drugs with 11 or more claims each, at $10,483 in total drug cost. In 2023, CMS named 195 claims across 9 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 78 out of 100 for Dr. Iyer for performance year 2024, reported as part of a group. Dr. Iyer accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Iyer as offering telehealth.

Dmand AI links 16 papers to Dr. Iyer, published from 2013 to 2025. 2025 was the busiest year, with 2. The most frequent topics are Antineoplastic Agents, Biomarkers, Tumor and Carcinoma, Transitional Cell. Dr. Iyer has published most often in Ann Oncol. Dr. Iyer's most frequent co-authors are Jonathan Eric Rosenberg, MD, Bernard H. Bochner, MD and James J. Harding, MD.

Dmand AI links Dr. Iyer to 5 clinical trials, 2 of them phase 1 studies. 5 are still active or recruiting. Conditions studied include Urinary Bladder Neoplasms, Carcinoma, Transitional Cell and Non-Muscle Invasive Bladder Neoplasms. Memorial Sloan Kettering Cancer Center sponsors the most, 2.

CMS Open Payments shows 61 general payments to Dr. Iyer from 15 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 78% of the total. EMD Serono, Inc. paid the most, $19,894. It also lists 14 research payments totaling $16,280 from 2024 to 2025.

Dr. Iyer graduated from Vanderbilt University School Of Medicine in 2003.

Dr. Iyer is in network with 12 carriers, including Aetna, Excellus BlueCross BlueShield and United Healthcare. PPO plans come from the most carriers, 8. Check the plan with the practice before a visit.